63rd ASH Annual Meeting and Exposition: 704. Cellular Immunotherapies: Allogeneic CARs and CARs for T Cell Lymphomas

Oral and Poster Abstracts
Oral

Biological therapies, Workforce, Therapies, Immunotherapy

Sidney Marcus Auditorium, Level 4, Building A (Georgia World Congress Center)

Moderators:

Abdul-Hamid Bazarbachi, MD, EBMT Paris study office / CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Paris, France, Université Pierre et Marie Curie, Paris, France and Razan Mohty, MD, American University of Beirut Medical Center

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

649

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Lazaros J. Lekakis¹^*, Frederick L. Locke, MD², Michael Tees, MD, MPH³, Sattva S. Neelapu, MD⁴, Shahbaz A. Malik, MD⁵, Mehdi Hamadani, MD⁶, Matthew J. Frank, MD, PhD⁷, Leslie L. Popplewell, MD, FACP⁸, Jeremy S. Abramson, MD⁹, Sven de Vos¹⁰, Javier Munoz, MD, MS, MBA, FACP¹¹, Chu Ri Shin, MD¹²^*, Arun Balakumaran, MD, PhD¹², Lynn Loomis-Navale, MSc¹²^*, Lovely Goyal, PhD¹²^*, Xiangdong Zhou, PhD¹²^* and David B. Miklos, MD, PhD⁷

¹Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
²Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
³Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, CO
⁴Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
⁵Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
⁶BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
⁷Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA
⁸Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
⁹Massachusetts General Hospital Cancer Center, Boston, MA
¹⁰University of California-Los Angeles, Los Angeles, CA
¹¹Mayo Clinic, Phoenix, AZ
¹²Allogene Therapeutics, South San Francisco, CA

10:45 AM

650

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin Jain, MD¹, Hagop Kantarjian, MD¹, Scott R. Solomon, MD², Fiona He, MD³, Craig S. Sauter, MD⁴, Christopher R. Heery, MD⁵, Alan F. List, MD⁵, Mark C. Johnson, PhD⁵^*, Yu Lou, MSc⁵^*, Monika Vainorius, MD⁵^*, Koen Van Besien, MD, PhD⁶, Adam J. Olszewski, MD⁷, Anthony S. Stein, MD⁸ and Bijal D. Shah, MD⁹

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Northside Hospital Cancer Institute, Atlanta, GA
³University of Minnesota, Minneapolis, MN
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Precision BioSciences, Inc., Durham, NC
⁶Presbyterian/Weill Cornell Medical College, New York, NY
⁷Rhode Island Hospital, Providence, RI
⁸City of Hope National Medical Center, Duarte, CA
⁹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

11:00 AM

651

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS ¹, Michaela Liedtke, MD², Surbhi Sidana, MD³, Jeffrey V. Matous, MD⁴, Saurabh Chhabra, MD, MS⁵, Olalekan O. Oluwole, MBBS, MPH⁶, Shahbaz A. Malik, MD⁷, Shaji K Kumar, MD⁸, Rajneesh Nath, MD⁹, Faiz Anwer, MD¹⁰, Jose Carlos Cruz, MD¹¹, Sundar Jagannath¹², Myo Htut¹³, Noopur S. Raje, MD¹⁴, David S. Siegel, MD, PhD¹⁵, Erin E. Karski, MD¹⁶^*, Wade Lovelace¹⁶^*, Afrodite Lourbakos, PhD¹⁶^*, Srinand Ponnathapura Nandakumar, PhD¹⁶^*, Arun Balakumaran, MD, PhD¹⁶ and Parameswaran Hari⁵

¹Myeloma Service and Cellular Therapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
³Division of BMT and Cell Therapy, Stanford University Hospital, Stanford, CA
⁴Colorado Blood Cancer Institute, Denver, CO
⁵Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
⁶Vanderbilt University Medical Center, Nashville, TN
⁷Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
⁸Mayo Clinic, Rochester, MN
⁹Banner MD Anderson Cancer Center, Gilbert, AZ
¹⁰Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
¹¹Texas Transplant Institute, San Antonio, TX
¹²Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
¹³Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA
¹⁴Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
¹⁵John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
¹⁶Allogene Therapeutics, South San Francisco, CA

11:15 AM

652

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Junfang Yang^1,2^*, Xiao Yang¹^*, Ying Liu³^*, Qinglong Wang³^*, Hui Wang, MD^1,2^*, Jianqiang Li, PhD³ and Peihua Lu, MD^1,2,4

¹Beijing Lu Daopei Institute of Hematology, Beijing, China
²Hebei Yanda Lu Daopei Hospital, Langfang, China
³Hebei Senlang Biotechnology Co., Ltd., Shijiazhuang, China
⁴Department of Oncology, Capital Medical University, Beijing, China

11:30 AM

653

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Matthew J. Frigault, MD¹, Yi-Bin Chen, MD, MS², Kathleen M.E. Gallagher, PhD³^*, Nora K. Horick, MS⁴^*, Areej El-Jawahri, MD⁵, Irene Scarfò, PhD⁶, Marc Wehrli, MD, PhD⁶^*, Lu Huang, PhD⁶^*, Keagan Casey, BS⁷^*, Daniella Cook, BS⁷^*, Thomas Spitzer, MD⁸^*, Steven McAfee, MD⁸^*, Frederic I. Preffer, PhD⁹^*, Myriam Armant, PhD¹⁰^*, Kit L. Shaw, PhD¹¹^*, Heather Daley¹²^*, Sarah Nikiforow, MD, PhD¹²^*, Jerome Ritz, MD¹³ and Marcela V. Maus, MD⁷

¹HCTCT, Massachusetts General Hospital, Boston, MA
²Bone Marrow Transplant Program, Massachussets General Hospital Cancer Center, Boston, MA
³Massachusetts General Hospital, Harvard Medical School, Charlestown, MA
⁴Harvard Medical School, Boston, MA
⁵Blood and Marrow Transplant Program, Massachusetts General Hospital, Allston, MA
⁶Massachusetts General Hospital, Charlestown, MA
⁷Cancer Center, Massachusetts General Hospital, Boston, MA
⁸Massachusetts General Hospital, Boston, MA
⁹Massachusetts General Hospital Department of Pathology, Boston, MA
¹⁰TransLab, Boston Children's Hospital, Boston, MA
¹¹Dana-Farber Cancer Institute, Boston, MA
¹²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹³Dana-Farber Cancer Institute, Division of Hematologic Malignancies and Harvard Medical School, Boston, MA

11:45 AM

654

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, MD¹, LaQuisa C. Hill, MD¹, Tyler S. Smith²^*, Lina Yang, PhD¹^*, Blakely Boriskie³^*, Madhuwanti Srinivasan³^*, Huimin Zhang, BS¹^*, Silvana Perconti, MS¹^*, Birju Mehta³^*, Olga Dakhova, PhD³^*, Bambi J. Grilley, RPh¹^*, Helen E. Heslop, MD, DSc¹, Malcolm K. Brenner, MD, PhD¹^* and Maksim Mamonkin, PhD⁴

¹Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
²Texas Tech University Health Sciences Center, El Paso, TX
³Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
⁴Center for Cell and Gene Therapy, Center For Cell and Gene Therapy, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.O4.3 704. Cellular Immunotherapies: Allogeneic CARs and CARs for T Cell Lymphomas